RxDoctor Payments Data

Vasantha Hathwar, MD

Pulmonary Disease · Virginia Beach, VANPI 1669572608

Payments from drug & device makers

$12,813in general payments, 2019–2025

Across 619 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$2K
  • Intuitive Surgical$961
  • Boehringer Ingelheim$794
  • Actelion Pharmaceuticals US, Inc.$742
  • Mallinckrodt Hospital Products Inc.$550
  • plus $6K from 45 others

What the payments were for

  • Travel & lodging$9227%
  • Food & beverage$11,39389%
  • Education$4984%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,813 in reported general payments places this provider in the 75th percentile of 317 pulmonary disease providers in Virginia.

See all pulmonary disease providers in Virginia

Medicare billing

Part B allowed, 2024
$375,447
Medicare patients
1,250
Services billed
4,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$106,972
Breo ElliptaFluticasone/Vilanterol67$55,152
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$51,092
Spiriva RespimatTiotropium Bromide37$48,554
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr54$41,338
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$13,828
SymbicortBudesonide/Formoterol Fumarate15$6,244
Wixela InhubFluticasone Propion/Salmeterol30$4,380
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate26$3,583
Albuterol Sulfate HfaAlbuterol Sulfate115$2,992
Roflumilast30$2,803
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,785
Montelukast Sodium202$2,389
Ventolin HfaAlbuterol Sulfate17$1,897
Fluticasone Propionate29$1,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,922$203,462204 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$794$62,38151 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,503$57,33547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 317 pulmonary disease providers in Virginia.

Other pulmonary disease in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →